Significant 340B Drug Pricing Program Litigation May Impact 340B Scope – Life Sciences Perspectives
Significant 340B Drug Pricing Program Litigation May Impact 340B Scope
Two recent federal court cases signal new significant developments with respect to the 340B Drug Pricing Program. Specifically: (1) new federal district court litigation challenging a recent HRSA Notice involving 340B Program “child site” registration and eligibility; and (2) a court decision in other litigation that implicates the scope of the 340B “eligible patient” definition. Details regarding these developments are in the client alert.
Read the client alert here.